A strategic roadmap to sustain long-term growth


the portfolio


outstanding launches


in R&D


the organization

2015: a new strategic roadmap to respond to market challenges

A number of fundamental trends point to a positive outlook for the pharmaceutical industry.

  • The global population is growing and aging. Unmet medical needs remain high.
  • The industry has increased R&D productivity, and has returned to consistently launching a high number of innovative medicines.
  • Patients around the world, and a rising middle class in emerging markets, are demanding better care, empowered by access to new information.
  • It is a particularly exciting time scientifically and technologically, with the promise of genomics being realized, immuno-oncology transforming cancer treatments, big data generating new insights into disease, and digital technologies helping to transform care delivery.

At the same time, funding challenges, budget tightening and affordability will continue to put the entire Healthcare value chain under significant pressure. Even though we believe that the pharmaceutical portion will remain a fundamentally attractive business, the bar for innovation will most likely continue to rise.

Innovation must have demonstrable benefit to the system. Payers will continue to put scrutiny on prices and reimbursement and will demand demonstration of real life outcomes, coupled with more innovative pricing and contracting practices.

Biosimilars are now firmly part of the competitive landscape in both the US and Europe. More focused competitors are building leadership positions in their priority therapy areas.

To compete and win in this market, we are implementing our 2020 strategic roadmap, announced in November 2015. We have made significant progress against each of the four pillars of that strategy in 2017: reshape the portfolio, deliver outstanding launches, sustain innovation in R&D, and simplify the organization.

The four pillars

Reshape the portfolio

To reshape the portfolio, we segmented our businesses focusing on three targets:

  • Sustain our leadership in Diabetes and Cardiovascular Diseases, Vaccines, Rare Diseases and Emerging Markets
  • Build competitive positions in Multiple Sclerosis, Oncology, Immunology and Consumer Healthcare
  • Explore strategic options for Animal Health and European Generics: Sanofi fully exited the Animal Health business in 2017 and announced the implementation of a divestiture process of the Generics business in Europe (following completion of the dialogue with social partners).


Creating a new franchise dedicated to rare blood disorders

With the acquisition of Bioverativ, global leader on the hemophilia market, and the planned acquisition of Ablynx, a biopharmaceutical company specialized in Nanobodies®, Sanofi should expand its presence in specialty care and set up a platform that should ensure its growth in rare blood disorders.

Deliver outstanding launches

Sanofi’s second strategic priority is to deliver outstanding launches of new medicines and vaccines. We have focused the organization on six major product launches: Toujeo®, Praluent®, Dengvaxia®, Soliqua 100/33 / Suliqua, Kevzara®, and Dupixent®.


Creating a new Immunology franchise with Dupixent® and Kevzara®

In 2017 Sanofi launched Dupixent®, the first and only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis. Dupixent® uptake to date is being driven by high patient need, healthcare professional engagement and initial market access. Also in 2017, Sanofi launched Kevzara® for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

Sustain innovation in Research & Development

Continued innovation in R&D is at the heart of Sanofi’s strategy. We are committed to responding to patients’ needs through the provision of adapted solutions which improve well-being and prolong life.

Sanofi has continuously adapted its R&D model in recent years to enhance its development excellence, which has had the effect of significantly improving the productivity of its portfolio.

Sanofi's portfolio has been rebalanced and reoriented towards biologics, especially through our collaboration with Regeneron for monoclonal antibodies. At the same time, our teams have worked internally to develop our own proprietary platforms, such as multi-specific antibodies which will allow the design of drugs with a mechanism of action making it possible to reach several targets at once.

Sustain innovation

Sustain innovation

Sanofi hosted an analyst meeting to discuss Sanofi’s R&D strategy and development pipeline on December 13, 2017 in Paris, France. The company highlighted the progress it has made against “Sustaining Innovation”, and advancing a differentiated portfolio addressing unmet needs.

Simplify the organization

  • Establishing a more agile organization through a cost reduction program
  • Uniting the different parts of the company behind a single vision, a common set of values and a shared culture

Global business units


This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies